Loading…
Employees: 167
Size Mobia Medical (MOBI) is a United States Health Care company (Medical Specialties) with a market value of $373M, the 2915th largest of 3,117 United States companies the cockpit tracks. Shares closed at $11.19 on 6 Nov 2026.
Growth Revenue grew 104.8% over the last twelve months (peer median +6.8%); the operating margin is -144.7% (peer median 8.1%).
Valuation It trades at 6.4× enterprise value to sales against a peer median of 3.7× (6th most expensive of 20).
Short interest Short interest is 2.5% of the free float (15 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $32.0M | $15.6M |
| Revenue growth | — | +105% | — |
| Gross profit | n/a | $25.8M | $12.3M |
| EBITDA | n/a | -$46.2M | -$24.1M |
| Net income | n/a | -$46.5M | -$24.6M |
| Free cash flow | n/a | -$46.1M | -$24.4M |
| Capital expenditure | n/a | $364,411 | $40,848 |
| Total debt | $8.43M | $8.44M | $7.72M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MOBI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +30.7% | -9.5% | highest of 21 |
| Distance from 52-week high | -26.8% | -38.2% | 7th highest of 21 |
| Revenue growth (TTM) | +104.8% | +6.8% | 2nd highest of 20 |
| Operating margin | -144.7% | 8.1% | 3rd lowest of 20 |
| EV / Sales | 6.4× | 3.7× | 6th most expensive of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mobia Medical MOBI | United States | $373M | n/a | +105% | -145% | 6.4× | n/a | n/a |
| Jiangsu Apon Medical Technology 300753.SZ | China | $376M | -27% | -15% | -10% | 8.0× | 22.4% | -5.1% |
| InBody 041830.KS | South Korea | $378M | +43% | +21% | 19% | 1.4× | -7.6% | +16.9% |
| Star Sports Medicine 1609.HK | Hong Kong | $367M | -76% | +23% | 37% | 3.7× | -13.2% | +36.8% |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $380M | -23% | -8% | 17% | 6.0× | 20.0% | +4.4% |
| IVF HARTMANN VBSN.SW | Switzerland | $364M | -5% | +7% | 14% | 1.1× | -12.7% | -1.3% |
| COLTENE CLTN.SW | Switzerland | $361M | +3% | -2% | 8% | 1.4× | 0.1% | -0.7% |
| Nanjing Medlander Medical Technology 688273.SS | China | $385M | -44% | -12% | 8% | 5.0× | 39.0% | +5.2% |
| Clarity Pharmaceuticals CU6.AX | Australia | $386M | -48% | n/a | n/a | n/a | n/a | n/a |
| OrbusNeich Medical 6929.HK | Hong Kong | $389M | -3% | +16% | 23% | 1.0× | -18.5% | +15.4% |
| Chongqing Xishan Science and Technology 688576.SS | China | $356M | -26% | -23% | -29% | 6.5× | n/a | n/a |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $352M | -27% | +12% | -2% | 8.1× | n/a | n/a |
| Taidoc Technology 4736.TW | Taiwan | $395M | 0% | -6% | 18% | 1.9× | -8.0% | -6.6% |
| Embecta EMBC | United States | $351M | +70% | -8% | 26% | 1.6× | -19.9% | -0.1% |
| ACRO Biomedical 6748.TWO | Taiwan | $347M | +129% | +45% | -178% | 200.7× | n/a | n/a |
| BioNote 377740.KS | South Korea | $343M | -10% | +13% | 16% | 0.8× | -19.8% | -28.5% |
| Chemclin Diagnostics 688468.SS | China | $342M | -23% | -14% | 6% | 6.2× | 31.9% | -4.5% |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $406M | -13% | +7% | 11% | 2.0× | -2.5% | -6.0% |
| Orchestra BioMed OBIO | United States | $341M | +41% | +986% | -181% | 9.8× | n/a | n/a |
| Ningbo Tianyi Medical Appliance 301097.SZ | China | $407M | -20% | +46% | 8% | 4.3× | n/a | n/a |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $407M | -14% | +3% | -45% | 1.9× | n/a | n/a |